Dergiler / Turkish Journal of Cancer / 2003 / Cilt: 33 - Sayı: 1

Retrospective evaluation of operated stage I breast cancer patients

Sayfa
40–50
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Follow-up period was short and long-term follow-up is necessary for better analysis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:As there is no national screening programme in our country, information about stage I breast carcinoma is limited.
📊
Temel Bulgular & Veri:In this study, 131 stage I breast cancer patients followed between April 1989 and March 2001 at our department, were retrospectively evaluated.
💡
Sonuç & Katkı:Follow-up period was short and long-term follow-up is necessary for better analysis.
🔬Tür:Araştırma Makalesi
📍Kapsam:2001 Verileri
⚙️Değişkenler:Kemoterapi · adjuvan · Kombine tedavi uygulaması

Abstract

As there is no national screening programme in our country, information about stage I breast carcinoma is limited. In this study, 131 stage I breast cancer patients followed between April 1989 and March 2001 at our department, were retrospectively evaluated. Median age was 49 (range: 26-77). Painless breast mass was the most common symptom (75%). Tumor size was larger than 1 cm in 66% of the patients. Seven percent of the patients had no adjuvant therapy, 43% had adjuvant tamoxifen and 50% had adjuvant chemotherapy ± tamoxifen. CMF combination (± tamoxifen) was the most common (71%) adjuvant chemotherapy regimen. Median follow-up period was 43 (range: 5+-148+) months. During the follow-up period, 1 patient had local recurrence and distant metastases, 3 had distant metastasis, and 5 patients (3.8%) had metachronous breast carcinoma. Two patients died with distant metastasis. Median disease free survival and median overall survival were not reached. Five-year disease free survival was 97% and, 5-year overall su rvival was 98.5%. Follow-up period was short and long-term follow-up is necessary for better analysis.

🔖

Bu Makaleye Atıf Yap

ÖKSÜZOĞLU, B., GÜLER, N., BALTALI, E., KARAOĞLU, A., ÖZIŞIK, Y., ALTUNDAĞ, K., TEKUZMAN, G. (2003). Retrospective evaluation of operated stage I breast cancer patients. Turkish Journal of Cancer, Cilt: 33 - Sayı: 1, 40–50. https://ajindex.com/articles/368478

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer Statistics, 2001. CA Cancer J Clin 2001;51:15-36
  2. Leitner SP, Swern AS, Weinberger D, et al. Predictors of recurrence for patients with small (one centimeter or less localized breast cancer (T1a,bN0M0). Cancer 1995;76:2266-74
  3. Rosner D, Lane WW. Predicting recurrence in axillarynode negative breast cancer patients. Breast Cancer Res Treat 1993;25:127-39
  4. Abner AL, Collins L, Peiro G, et al. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer 1998;83:2502- 8
  5. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001;19:3817-27
  6. Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001;1651-716
  7. Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7
  8. Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer 1999;85:2183- 9
  9. Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimetre or less and negative axillary lymph nodes. J Natl Cancer Inst 2001;93:112-20
  10. Oran B. Postmenopozal Meme Kanseri Hastalarinda Adjuvan Siklofosfamid, Metotreksat, Flourourasil Tedavisinin Genel ve Hastaliksiz Sagkalima Etkisinin Incelenmesi. Uzmanlik Tezi, Hacettepe Üniversitesi Tip Fakültesi, Iç Hastaliklari Anabilim Dali, Ankara, 2001
  11. Oyan B, Güler N, Kars A, et al. The prognostic predictors for disease-free survival and overall survival in stage IIII breast carcinoma patients treated with adjuvant cyclophosphamide- adriamycine-5 fluorouracil (CAF) chemotherapy. Turk J Cancer 2002;32:92-104
  12. Altundag MK, Yalçin S, Baltali E ve ark. Premenopozal opere evre I-IIIA meme kanserli hastalarda adjuvan siklofosfamid- metotreksat-5 fluorourasil (CMF) sonuçlarinin incelenmesi. Türk Hematoloji Onkoloji Dergisi 2000;2:61-9. 1 3. Lee AKC, Loda M, Mackarem G, et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0). Clinicopathologic features and outcome. Cancer 1997;79:761-71. 1 4. Fisher D, Redmond C, Poisson R, et al. Eight-year results of randomised clinical tr